EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study

Marco Sposito, Lorenzo Belluomini, Riccardo Nocini, Jessica Insolda, Ilaria Mariangela Scaglione, Jessica Menis, Michele Simbolo, Antonio Lugini, Federica Buzzacchino, Francesco Verderame, Francesca Spinnato, Giuseppe Aprile und 17 weitere

Frontiers in Oncology · 09.07.2024 · 14

DOI: 10.3389/fonc.2024.1436588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.07.2024. Verfasst von Marco Sposito und 28 weiteren Autor:innen. Beteiligte Einrichtung: Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and …. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To date, for all non-small cell lung cancer (NSCLC) cases, it is recommended to test for driver alterations to identify actionable therapeutic targets. In this light, comprehensive genomic profiling (CGP) with next generation sequencing (NGS) has progressively gained increasing importance in clinical practice. Here, with the aim of assessing the distribution and the real-world frequency of gene alterations and their correlation with patient characteristics, we present the outcomes obtained using FoundationOne (F1CDx) and FoundationLiquid CDx (F1L/F1LCDx) NGS-based profiling in a nationwide initiative for advanced NSCLC patients.

Methods

F1CDx (324 genes) was used for tissue samples, and F1L (70 genes) or F1LCDx (324 genes) for liquid biopsy, aiming to explore the real-world occurrence of molecular alterations in aNSCLC and their relationship with patients’ characteristics.

Results

Overall, 232 advanced NSCLC patients from 11 Institutions were gathered [median age 63 years; never/former or current smokers 29.3/65.9%; adenocarcinoma/squamous 79.3/12.5%; F1CDx/F1L+F1LCDx 59.5/40.5%]. Alterations were found in 170 different genes. Median number of mutated genes per sample was 4 (IQR 3–6) and 2 (IQR 1–3) in the F1CDx and F1L/F1LCDx cohorts, respectively. TP53 (58%), KRAS (22%), CDKN2A/B (19%), and STK11 (17%) alterations were the most frequently detected. Actionability rates (tier I and II) were comparable: 36.2% F1CDx vs. 34% ctDNA NGS assays (29.5% and 40.9% F1L and F1LCDx, respectively). Alterations in KEAP1 were significantly associated with STK11 and KRAS , so as TP53 with RB1 . Median tumor mutational burden was 6 (IQR 3–10) and was significantly higher in smokers. Median OS from metastatic diagnosis was 23 months (IQR 18.5–19.5) and significantly lower in patients harboring ≥3 gene mutations. Conditional three-year survival probabilities increased over time for patients profiled at initial diagnosis and exceeded those of individuals tested later in their clinical history after 12 months.

Conclusion

This study confirms that NGS-based molecular profiling of aNSCLC on tissue or blood samples offers valuable predictive and prognostic insights.

Schlagwörter

Stichwörter der Autor:innen

liquid biopsynext generation sequencingnon-small cell lung cancerprecision medicinetarget therapy

Autor:innen und Institutionen

  • Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Ver…
  • Otolaryngology-Head and Neck Surgery Department, University of Verona Hospital Trust, Verona, Italy.
  • Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy.
  • Medical Oncology Unit, Azienda Ospedaliera (AO) San Giovanni Addolorata Hospital, Rome, Italy.
  • Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy.
  • Section of Oncology, Azienda Ospedaliera (AO) Ospedali Riuniti "Villa Sofia- V. Cervello", Palermo, Italy.

Zitieren

APA

Sposito, M., Belluomini, L., Nocini, R., Insolda, J., Scaglione, I. M., Menis, J., Simbolo, M., Lugini, A., Buzzacchino, F., Verderame, F., Spinnato, F., Aprile, G., Calvetti, L., Occhipinti, M., Marinelli, D., Veccia, A., Lombardo, F., Soto Parra, H. J., Ferraù, F., …, & Milella, M. (2024). Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1436588

Vancouver

Sposito M, Belluomini L, Nocini R, Insolda J, Scaglione IM, Menis J, et al. Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1436588

BibTeX
@article{Sposito2024,
  author = {Sposito, Marco and Belluomini, Lorenzo and Nocini, Riccardo and Insolda, Jessica and Scaglione, Ilaria Mariangela and Menis, Jessica and Simbolo, Michele and Lugini, Antonio and Buzzacchino, Federica and Verderame, Francesco and Spinnato, Francesca and Aprile, Giuseppe and Calvetti, Lorenzo and Occhipinti, Mario and Marinelli, Daniele and Veccia, Antonello and Lombardo, Fiorella and Soto Parra, Hector José and Ferraù, Francesco and Savastano, Clementina and Porta, Camilla and Pradelli, Lorenzo and Sicari, Emilia and Castellani, Silvia and Malapelle, Umberto and Novello, Silvia and Bria, Emilio and Pilotto, Sara and Milella, Michele},
  title = {Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1436588}
}
Kostenlos starten →